Spyre Therapeutics priced a $350 million offering to prepare for Phase III and advance SPY072 for hidradenitis suppurativa. Get the key funding details.

A Phase III trial will test MRD-guided giredestrant and CDK4/6 inhibitor use in early breast cancer. Explore the study design and its potential impact.

Equillium wins Australian clearance to begin EQ504's first-in-human Phase I trial. Read what the approval means for the biotech's clinical development.

M in an IPO to advance its Treg pipeline toward Phase II, with Lilly as collaborator and investor. Read the offering details.

Gate Bioscience expands its Lilly deal for hard-to-drug proteins, with potential value above $870m. Read the latest on the ...

RougeTx raised $58 million in Series A funding to advance its HHT treatment toward clinical development. See who backed the ...

Italfarmaco and VeriSIM Life will combine AI and HDAC expertise in a preclinical drug discovery deal worth over USD 100 ...

Shionogi will acquire IntraBio for $2 billion upfront, adding AQNEURSA for rare neurological diseases. See what the deal means for its portfolio. Read more.

Vaxcyte says its 31-valent VAX-31 vaccine met all primary endpoints in the OPUS-1 Phase III trial in adults aged 50 and older. Read the topline results.

Sernova and Seraxis closed $11.2 million to fund merger and advance BetaNova’s type 1 diabetes cell therapy into Phase 1/2 ...

Alector will receive $100M upfront as Genentech gains worldwide rights to its brain-penetrant GCase therapy for Parkinson’s.

Nhwa licensed its sleep-disorder drug to Somnivera outside Greater China in a deal worth up to $517 million. Read key deal terms and milestone details.